GlassScriptPhysician profile
David A Judish
NPI 1720030802
$2,226.75
in general payments reported to CMS, 2019-2025
25 companies · $731 in 2025
The $731 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.29 · 2023: $633 · 2024: $805 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.07 | 2023-2025 | |
| Novo Nordisk INC | $336.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $204.57 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Myriad Women'S Health, INC. | $159.21 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $146.91 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $131.18 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.26 | 2023-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $98.25 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $74.18 | 2024-2025 | |
| Pfizer INC. | $73.45 | 2023-2025 | |
| Medtronic, INC. | $69.83 | 2024-2025 | Intellis Adaptivestim, Venaseal |
| Seqirus USA INC | $60.08 | 2022-2025 | Flucelvax, Fluad |
| Exact Sciences Corporation | $58.23 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.92 | 2022-2024 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $44.62 | 2023-2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $43.25 | 2023-2025 | Veozah |
| Ironshore Pharmaceuticals INC. | $37.93 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.10 | 2024 | Trintellix |
| Organon LLC | $24.35 | 2024 | |
| Gilead Sciences, INC. | $23.27 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2025 | Breztri |
| Ibsa Pharma INC. | $20.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.62 | 2023 | Quviviq |
| Corium, LLC | $14.02 | 2024 | Azstarys |
| Phathom Pharmaceuticals, INC. | $12.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Judish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.